Jing Yi1, Li Lu2, Kilangsungla Yanger3,4, Wenqi Wang5, Bo Hwa Sohn6, Ben Z Stanger3,4,7, Min Zhang8, James F Martin8, Jaffer A Ajani9, Junjie Chen5, Ju-Seog Lee6, Shumei Song9, Randy L Johnson10,11,12. 1. Department of Cancer Biology, MD Anderson Cancer Center, University of Texas, Houston, TX. 2. Department of Genetics, MD Anderson Cancer Center, University of Texas, Houston, TX. 3. Department of Medicine, Gastroenterology Division, University of Pennsylvania School of Medicine, Philadelphia, PA. 4. Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA. 5. Department of Experimental Radiation Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX. 6. Department of Systems Biology, MD Anderson Cancer Center, University of Texas, Houston, TX. 7. Department of Cell and Developmental Biology, University of Pennsylvania School of Medicine, Pennsylvania, PA. 8. Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX. 9. Department of GI Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX. 10. Department of Cancer Biology, MD Anderson Cancer Center, University of Texas, Houston, TX. rljohnso@mdanderson.org. 11. Genes & Development Program, Graduate School of Biomedical Sciences, University of Texas Health Sciences Center, Houston, TX. rljohnso@mdanderson.org. 12. Developmental Biology Program, Baylor College of Medicine, Houston, TX. rljohnso@mdanderson.org.
Abstract
In the adult liver, the Hippo pathway mammalian STE20-like protein kinases 1 and 2 and large tumor suppressor homologs 1 and 2 (LATS1/2) control activation of the transcriptional coactivators Yes-associated protein (YAP) and WW domain containing transcription regulator 1 (TAZ) in hepatocytes and biliary epithelial cells, thereby regulating liver cell proliferation, differentiation, and malignant transformation. Less is known about the contribution of Hippo signaling to liver development. We used conditional mutagenesis to show that the Hippo signaling pathway kinases LATS1 and LATS2 are redundantly required during mouse liver development to repress YAP and TAZ in both the biliary epithelial and hepatocyte lineages. In the absence of LATS1/2, biliary epithelial cells exhibit excess proliferation while hepatoblasts fail to mature into hepatocytes, defects that result in perinatal lethality. Using an in vitro hepatocyte differentiation assay, we demonstrate that YAP activity decreases and Hippo pathway kinase activities increase upon differentiation. In addition, we show that YAP activation in vitro, resulting from either depletion of its negative regulators LATS1/2 or expression of a mutant form of YAP that is less efficiently phosphorylated by LATS1/2, results in transcriptional suppression of genes that normally accompany hepatocyte maturation. Moreover, we provide evidence that YAP activity is repressed by Hippo pathway activation upon hepatocytic maturation in vitro. Finally, we examine the localization of YAP during fetal liver development and show that higher levels of YAP are found in biliary epithelial cells, while in hepatocytes YAP levels decrease with hepatocyte maturation. CONCLUSION: Hippo signaling, mediated by the LATS1 and LATS2 kinases, is required to restrict YAP and TAZ activation during both biliary and hepatocyte differentiation. These findings suggest that dynamic regulation of the Hippo signaling pathway plays an important role in differentiation and functional maturation of the liver. (Hepatology 2016;64:1757-1772).
In the adult liver, the Hippo pathway mammalian STE20-like protein kinases 1 and 2 and large tumor suppressor homologs 1 and 2 (LATS1/2) control activation of the transcriptional coactivators Yes-associated protein (YAP) and WW domain containing transcription regulator 1 (TAZ) in hepatocytes and biliary epithelial cells, thereby regulating liver cell proliferation, differentiation, and malignant transformation. Less is known about the contribution of Hippo signaling to liver development. We used conditional mutagenesis to show that the Hippo signaling pathway kinases LATS1 and LATS2 are redundantly required during mouse liver development to repress YAP and TAZ in both the biliary epithelial and hepatocyte lineages. In the absence of LATS1/2, biliary epithelial cells exhibit excess proliferation while hepatoblasts fail to mature into hepatocytes, defects that result in perinatal lethality. Using an in vitro hepatocyte differentiation assay, we demonstrate that YAP activity decreases and Hippo pathway kinase activities increase upon differentiation. In addition, we show that YAP activation in vitro, resulting from either depletion of its negative regulators LATS1/2 or expression of a mutant form of YAP that is less efficiently phosphorylated by LATS1/2, results in transcriptional suppression of genes that normally accompany hepatocyte maturation. Moreover, we provide evidence that YAP activity is repressed by Hippo pathway activation upon hepatocytic maturation in vitro. Finally, we examine the localization of YAP during fetal liver development and show that higher levels of YAP are found in biliary epithelial cells, while in hepatocytes YAP levels decrease with hepatocyte maturation. CONCLUSION: Hippo signaling, mediated by the LATS1 and LATS2 kinases, is required to restrict YAP and TAZ activation during both biliary and hepatocyte differentiation. These findings suggest that dynamic regulation of the Hippo signaling pathway plays an important role in differentiation and functional maturation of the liver. (Hepatology 2016;64:1757-1772).
Authors: N Kojima; T Kinoshita; A Kamiya; K Nakamura; K Nakashima; T Taga; A Miyajima Journal: Biochem Biophys Res Commun Date: 2000-10-14 Impact factor: 3.575
Authors: Dean Yimlamai; Constantina Christodoulou; Giorgio G Galli; Kilangsungla Yanger; Brian Pepe-Mooney; Basanta Gurung; Kriti Shrestha; Patrick Cahan; Ben Z Stanger; Fernando D Camargo Journal: Cell Date: 2014-06-05 Impact factor: 41.582
Authors: Mei Xin; Yuri Kim; Lillian B Sutherland; Xiaoxia Qi; John McAnally; Robert J Schwartz; James A Richardson; Rhonda Bassel-Duby; Eric N Olson Journal: Sci Signal Date: 2011-10-25 Impact factor: 8.192
Authors: Dawang Zhou; Claudius Conrad; Fan Xia; Ji-Sun Park; Bernhard Payer; Yi Yin; Gregory Y Lauwers; Wolfgang Thasler; Jeannie T Lee; Joseph Avruch; Nabeel Bardeesy Journal: Cancer Cell Date: 2009-11-06 Impact factor: 31.743
Authors: Joshua M Adams; Kari A Huppert; Eumenia C Castro; Mario F Lopez; Nima Niknejad; Sanjay Subramanian; Neda Zarrin-Khameh; Milton J Finegold; Stacey S Huppert; Hamed Jafar-Nejad Journal: Hepatology Date: 2020-01-24 Impact factor: 17.425
Authors: Jennifer L Cotton; Qi Li; Lifang Ma; Joo-Seop Park; Jiayi Wang; Jianhong Ou; Lihua J Zhu; Y Tony Ip; Randy L Johnson; Junhao Mao Journal: Dev Cell Date: 2017-09-21 Impact factor: 12.270
Authors: Juan Mo; Jean-Philippe Brosseau; Zhiguo Chen; Tracey Shipman; Yong Wang; Chung-Ping Liao; Jonathan M Cooper; Robert J Allaway; Sara J C Gosline; Justin Guinney; Thomas J Carroll; Lu Q Le Journal: Cancer Discov Date: 2018-10-22 Impact factor: 39.397
Authors: Qi Li; Yang Sun; Gopala K Jarugumilli; Shun Liu; Kyvan Dang; Jennifer L Cotton; Jordi Xiol; Pui Yee Chan; Michael DeRan; Lifang Ma; Rui Li; Lihua J Zhu; Joyce H Li; Andrew B Leiter; Y Tony Ip; Fernando D Camargo; Xuelian Luo; Randy L Johnson; Xu Wu; Junhao Mao Journal: Cell Stem Cell Date: 2020-04-06 Impact factor: 24.633